|
'''Apolizumab''' is a humanized ] intended for use in hematologic ]s.<ref>{{cite journal | title = Gateways to clinical trials | journal = Methods Find Exp Clin Pharmacol | volume = 25 | issue = 9 | pages = 747–71 | year = 2003 | pmid = 14685303 | author1 = Bayes M | author2 = Rabasseda X | author3 = Prous J }}</ref><ref>{{cite journal | pmid=17071489 | year=2006 | last1=Rech | first1=J | last2=Repp | first2=R | last3=Rech | first3=D | last4=Stockmeyer | first4=B | last5=Dechant | first5=M | last6=Niedobitek | first6=G | last7=Gramatzki | first7=M | last8=Valerius | first8=T | title=A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study | volume=47 | issue=10 | pages=2147–54 | doi=10.1080/10428190600757944 | journal=Leukemia & Lymphoma | s2cid=24080973}}</ref> Development was abandoned in 2005, because of toxic effects and lack of efficacy in humans. The observed dose limiting toxic effects were ] and ].<ref>{{cite journal | vauthors=Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC | title=A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia | journal=Leuk. Lymphoma | volume=50 | issue=12 | pages=1958–63 | date=December 2009 | pmid=19860603 | doi=10.3109/10428190903186486 | s2cid=22328921 | url= | pmc=8166408 }}</ref> |
|
'''Apolizumab''' is a humanized ] intended for use in hematologic ]s.<ref>{{cite journal | vauthors = Bayes M, Rabasseda X, Prous JR | title = Gateways to clinical trials | journal = Methods and Findings in Experimental and Clinical Pharmacology | volume = 25 | issue = 9 | pages = 747–771 | date = November 2003 | pmid = 14685303 }}</ref><ref>{{cite journal | vauthors = Rech J, Repp R, Rech D, Stockmeyer B, Dechant M, Niedobitek G, Gramatzki M, Valerius T | display-authors = 6 | title = A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study | journal = Leukemia & Lymphoma | volume = 47 | issue = 10 | pages = 2147–2154 | date = October 2006 | pmid = 17071489 | doi = 10.1080/10428190600757944 | s2cid = 24080973 }}</ref> Development was abandoned in 2005, because of toxic effects and lack of efficacy in humans. The observed dose limiting toxic effects were ] and ].<ref>{{cite journal | vauthors = Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC | display-authors = 6 | title = A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia | journal = Leukemia & Lymphoma | volume = 50 | issue = 12 | pages = 1958–1963 | date = December 2009 | pmid = 19860603 | pmc = 8166408 | doi = 10.3109/10428190903186486 | s2cid = 22328921 }}</ref> |
